DePuy Orthopaedics, Inc., ASR Hip Implant

The DePuy ASR hip implant MDL, now well into its second decade, retains 113 pending actions against a much larger historical filing population — a profile typical of a docket that moved through its major settlement programs years ago and is now working through a defined residual tail rather than an open-ended intake pipeline. For a funder, that maturity is itself informative: metal-on-metal hip-implant failure mechanisms (elevated metal-ion levels, tissue damage, and revision-surgery rates) have been extensively litigated and characterized in this docket, and prior settlement structures provide real pricing comparables for what remains.

Funding availability for a claim still active in this docket should be evaluated against that residual-tail profile: these are more likely to be later-diagnosed revision cases, claims with atypical damages (extended revision surgery, chronic pain, or additional corrective procedures), or matters that fell outside the parameters of earlier settlement programs. That context changes both the expected timeline and the appropriate advance sizing relative to a fresh, early-stage filing.

Medical-lien considerations are central to this docket given the nature of the injury — hip-implant failure claims typically carry substantial associated treatment costs, including revision-surgery expenses, and any portfolio or single-case evaluation needs a clear-eyed view of lien exposure against expected recovery. For a law firm holding a meaningful number of these residual claims, portfolio-level inventory finance remains a reasonable structure, provided the underwriting reflects that this is a late-stage, not early-stage, claim population.

Because the major settlement architecture for this docket is already established rather than prospective, duration risk for remaining claims is now driven more by individual claim processing and any residual settlement-program mechanics than by docket-wide bellwether uncertainty. Criterica Capital's mass-tort finance line, together with medical-lien receivables financing where relevant, fits this later-stage claim profile.

A structural litigation brief on this docket's procedural history and settlement architecture is also available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.